AWHL.US Aspira Women's Health Inc.

Healthcare Diagnostics & Research USA Stocks
0.1900 USD
Close of Nov 14, 2026
0.1300 0.6788
Market cap
USD 8.86M
P/E
-
P/B
5.02x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is AWHL.US undervalued?

Graham number

The Graham number of Aspira Women's Health Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Aspira Women's Health Inc. fundamental analysis

No fundamental analysis for Aspira Women's Health Inc. yet.

Aspira Women's Health Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Aspira Women's Health Inc.

Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; and OvaWatch, a assist in the initial and periodic clinical assessment of malignancy risk in all women thought to have an indeterminate or benign…

Full company profile